Severe eosinophilic is effectively treated with benralizumab, with especially good outcomes in patients with high BEC and high FeNO.

Effective implementation will require greater provision of tests, services, and support Asthma is a common inflammatory airway condition that affects around six million people in the UK.1 Despite ...

Gastrointestinal involvement is common among patients with EGPA, with eosinophilic tissue infiltration, weight loss, and ...

The SARS-CoV-2 pandemic interrupted much respiratory research. Respiratory clinical academics joined colleagues in providing clinical care, and global research efforts were directed to finding new ...

GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Limited (“Revolo”) today announced that it will present two posters on its lead candidate, ‘1104, at the 2025 ...

An estimated 5,000 people in the United States are living with Eosinophilic Granulomatosis with Polyangiitis (EGPA), a rare ...

Researchers observed that only 8.3% of 24 children or adolescents with peanut allergy passed a double-blind ...

Pre-treatment disease trajectories in severe asthma impact treatment-related outcomes, according to a study by Johannes ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Initially developed for atopic dermatitis, Enveda's lead asset ENV-294 is now showing promise in treating asthma.

During the 43rd J.P. Morgan Annual Healthcare Conference last month, Areteia Therapeutics took centre stage, presenting a ...

The leading Severe Asthma Companies such as Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology ...